What is a primary therapeutic use for Eptifibatide?

Eptifibatide is a glycoprotein IIb/IIIa inhibitor that is primarily used in the management of acute coronary syndrome (ACS). Its main therapeutic purpose is to reduce the risk of cardiac events in patients who are undergoing percutaneous coronary intervention (PCI) or those who have unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI). By inhibiting the aggregation of platelets, Eptifibatide helps prevent the formation of blood clots that can lead to heart attacks, thereby contributing to a reduction in mortality and morbidity associated with these conditions.

This specific action and therapeutic use make it crucial for treating patients during urgent cardiac situations, distinguishing it distinctly from treatments aimed at managing asthma, diabetes, or hypertension, which involve different mechanisms and drug classes.